The French National Cancer Institute (INCa)

Last updated: 06/01/2016

The French National Cancer Institute (INCa) is the preeminent health and science agency in charge of cancer control in France. Created under the Public Health Act of 9th August 2004, it is attached to both ministries of Health and Research.

The INCa is a public interest group (GIP) which brings together State representatives, large NGOs, health insurance funds, research organisations and hospital federations. These stakeholders share a common goal of reducing the incidence of avoidable cancers and the number of cancer deaths, improving the quality of life of people with cancer during and after their illness, and reducing inequalities related to cancer.

The INCa provides integrated undertakings in all dimensions (health, scientific, social and economic) and areas of intervention (prevention, screening, care and research) associated with malignant pathologies.

To catalyse progress, the INCa acts as an interface with patients, their friends and families, the healthcare system users, general public, healthcare professionals, researchers, experts and decision-makers.


  • To coordinate cancer control activities 
  • To initiate and support scientific, medical, technological and organisational innovation 
  • To contribute to the organisational framework 
  • To produce expertise 
  • To produce, analyse and evaluate data 
  • To promote knowledge, uptake and good practices 



  • To support emerging fields, i.e. genomic studies, experimental study models, biology and immunology 
  • To translate fundamental discoveries into advances for the benefit of the population and for patients — diagnostic tools, personalised treatments and quality of life — as fast as possible 
  • To increase the availability of biological and clinical resources to researchers 
  • To develop clinical trials in order to find effective treatments

Public health

  • To improve knowledge on cancer risk factors 
  • To promote behaviours changes to reduce the incidence of avoidable cancers 
  • To define and adapt screening strategies according to people's level of risk for cancer 
  • To continuously optimise the organisation of screening, by assessing and incorporating scientific and technical advances 
  • To disseminate information on cancer that is reliable and succinct.


  • To improve the coordination of patient-centred care, in the context of a personalised care pathway
  • To guarantee equal access to quality care.
  • To develop relavant care procedures for people with rare cancers, people with a genetic predisposition, elderly people, children and adolescents.
  • To support the evolvement of career paths in the cancer field.
  • To promote the improvement in the quality of life during and after the disease.


The INCa board of directors is made up of representatives of the core GIP members and of eight qualified individuals. It is supported by an International Scientific Advisory Board and three consultative bodies, namely an ethics committee, an audit committee and a users and professionals committee.
INCa has an annual budget of approximately 100 million. Most of it is received from the Ministries of Health and Research, contributions from other GIP members and funds from partnerships with public and private organisations. About half of this budget is allocated to research funding. The rest is allocated to healthcare initiatives, public health and public information.
INCa has 150 employees, and works with several hundred outside experts each year to contribute to its works.

Reports to download